Forum Exodus Continues as CSO Koenig Heads to Quartet

Xconomy Boston — 

Forum Pharmaceuticals shut down a few weeks ago, and now one of its top executives has resurfaced at a new company. Gerhard Koenig, Forum’s former chief scientific officer and head of research, has been named the CEO of Cambridge, MA-based Quartet Medicine, a startup developing pain drugs. Merck, in January, grabbed an exclusive option to buy Quartet at a later date. The startup’s founding CEO, former Atlas Venture venture partner Kevin Pojasek, is now the head of portfolio strategy at U.K.-based Immunocore, according to LinkedIn.